Validation of the real-world application of the Hidradenitis Suppurativa Quality of Life (HiSQOL) score to adults with hidradenitis suppurativa
The HiSQOL is a valid tool for assessing QoL in patients with HS in a real-world setting. Furthermore, the HiSQOL better captures aspects of HS that have the highest impact on QoL, including depression and anxiety, which are not captured by the DLQI.
Authors
- Russel Burge (ORCID: https://orcid.org/0000-0001-7907-6400)
- Sophie Barlow (ORCID: https://orcid.org/0000-0001-5604-1360)
- Andrea A. Cohee (ORCID: https://orcid.org/0000-0001-7928-6491)
- Amit Garg (ORCID: https://orcid.org/0000-0003-0886-6856)
- Hayley Wallinger
- Andrew Strunk (ORCID: https://orcid.org/0000-0002-7547-031X)
- Isabel Truman (ORCID: https://orcid.org/0000-0002-6055-2902)
- Aaron Keal (ORCID: https://orcid.org/0009-0004-6368-7476)
Institutions
- Northwell Health (US)
- Eli Lilly (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- North Shore Diabetes and Endocrine Associates (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1093/bjd/ljae367
- Citations
- 5
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.67